{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T09:37:26Z","timestamp":1794908246153,"version":"4.9.1"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2020,3,19]],"date-time":"2020-03-19T00:00:00Z","timestamp":1584576000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,3,19]],"date-time":"2020-03-19T00:00:00Z","timestamp":1584576000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["R01AI137472"],"award-info":[{"award-number":["R01AI137472"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["R01AI139092"],"award-info":[{"award-number":["R01AI139092"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"name":"U.S. Department of Health & Human Services | National Institutes of Health"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Mol Immunol"],"published-print":{"date-parts":[[2020,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The outbreak of Coronavirus Disease 2019 (COVID-19) has posed a serious threat to global public health, calling for the development of safe and effective prophylactics and therapeutics against infection of its causative agent, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), also known as 2019 novel coronavirus (2019-nCoV). The CoV spike (S) protein plays the most important roles in viral attachment, fusion and entry, and serves as a target for development of antibodies, entry inhibitors and vaccines. Here, we identified the receptor-binding domain (RBD) in SARS-CoV-2 S protein and found that the RBD protein bound strongly to human and bat angiotensin-converting enzyme 2 (ACE2) receptors. SARS-CoV-2 RBD exhibited significantly higher binding affinity to ACE2 receptor than SARS-CoV RBD and could block the binding and, hence, attachment of SARS-CoV-2 RBD and SARS-CoV RBD to ACE2-expressing cells, thus inhibiting their infection to host cells. SARS-CoV RBD-specific antibodies could cross-react with SARS-CoV-2 RBD protein, and SARS-CoV RBD-induced antisera could cross-neutralize SARS-CoV-2, suggesting the potential to develop SARS-CoV RBD-based vaccines for prevention of SARS-CoV-2 and SARS-CoV infection.<\/jats:p>","DOI":"10.1038\/s41423-020-0400-4","type":"journal-article","created":{"date-parts":[[2020,3,19]],"date-time":"2020-03-19T06:02:54Z","timestamp":1584597774000},"page":"613-620","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1479,"title":["Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccine"],"prefix":"10.1038","volume":"17","author":[{"given":"Wanbo","family":"Tai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiujuan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Pu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2652-0787","authenticated-orcid":false,"given":"Denis","family":"Voronin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shibo","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusen","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lanying","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,3,19]]},"reference":[{"key":"400_CR1","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1038\/nrmicro2090","volume":"7","author":"L Du","year":"2009","unstructured":"Du, L., He, Y., Zhou, Y., Liu, S., Zheng, B. J. & Jiang, S. The spike protein of SARS-CoV-a target for vaccine and therapeutic development. Nat. Rev. Microbiol. 7, 226\u2013236 (2009).","journal-title":"Nat. Rev. Microbiol."},{"key":"400_CR2","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2020.00298","author":"N Wang","year":"2020","unstructured":"Wang, N., Shang, J., Jiang, S. & Du, L. Subunit vaccines against emerging pathogenic human coronaviruses. Front. Microbiol. https:\/\/doi.org\/10.3389\/fmicb.2020.00298 (2020).","journal-title":"Front. Microbiol."},{"key":"400_CR3","unstructured":"World Health Organization. Naming the coronavirus disease (COVID-19) and the virus that causes it. https:\/\/www.who.int\/emergencies\/diseases\/novel-coronavirus-2019\/technical-guidance\/naming-the-coronavirus-disease-(covid-2019)-and-the-virus-that-causes-it (2020)."},{"key":"400_CR4","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1016\/S0140-6736(03)14630-2","volume":"362","author":"NS Zhong","year":"2003","unstructured":"Zhong, N. S. et al. Epidemiology and cause of severe acute respiratory syndrome (SARS) in Guangdong, People\u2019s Republic of China, in February, 2003. Lancet 362, 1353\u20131358 (2003).","journal-title":"Lancet"},{"key":"400_CR5","doi-asserted-by":"publisher","first-page":"1814","DOI":"10.1056\/NEJMoa1211721","volume":"367","author":"AM Zaki","year":"2012","unstructured":"Zaki, A. M., van Boheemen, S., Bestebroer, T. M., Osterhaus, A. D. & Fouchier, R. A. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N. Engl. J. Med. 367, 1814\u20131820 (2012).","journal-title":"N. Engl. J. Med."},{"key":"400_CR6","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1056\/NEJMoa2001017","volume":"382","author":"N Zhu","year":"2020","unstructured":"Zhu, N. et al. A novel coronavirus from patients with pneumonia in China, 2019. N. Engl. J. Med. 382, 727\u2013733 (2020).","journal-title":"N. Engl. J. Med."},{"key":"400_CR7","unstructured":"World Health Organization. Coronavirus disease 2019 (COVID-19)-Situation report-45. https:\/\/www.who.int\/docs\/default-source\/coronaviruse\/situation-reports\/20200305-sitrep-45-covid-19.pdf?sfvrsn=ed2ba78b_2 (2020)."},{"key":"400_CR8","doi-asserted-by":"publisher","unstructured":"Gorbalenya, A. E., et al. The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. Nat. Microbiol. https:\/\/doi.org\/10.1038\/s41564-020-0695-z (2020).","DOI":"10.1038\/s41564-020-0695-z"},{"issue":"10228","key":"400_CR9","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1016\/S0140-6736(20)30419-0","volume":"395","author":"Shibo Jiang","year":"2020","unstructured":"Jiang, S., Zhi, S., Shu, Y., Song, J., Gao, G. F., Tan, W., Guo, D. A distinct name is needed for the new coronavirus. Lacent. pii: S0140-6736(20)30419-0. https:\/\/doi.org\/10.1016\/S0140-6736(20)30419-0 (2020).","journal-title":"The Lancet"},{"key":"400_CR10","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1586\/14760584.2016.1167603","volume":"15","author":"L Du","year":"2016","unstructured":"Du, L., Tai, W., Zhou, Y. & Jiang, S. Vaccines for the prevention against the threat of MERS-CoV. Expert Rev. Vaccines 15, 1123\u20131134 (2016).","journal-title":"Expert Rev. Vaccines"},{"key":"400_CR11","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1080\/14760584.2018.1506702","volume":"17","author":"Y Zhou","year":"2018","unstructured":"Zhou, Y., Jiang, S. & Du, L. Prospects for a MERS-CoV spike vaccine. Expert Rev. Vaccines 17, 677\u2013686 (2018).","journal-title":"Expert Rev. Vaccines"},{"key":"400_CR12","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1080\/14728222.2017.1271415","volume":"21","author":"L Du","year":"2017","unstructured":"Du, L., Yang, Y., Zhou, Y., Lu, L., Li, F. & Jiang, S. MERS-CoV spike protein: a key target for antivirals. Expert Opin. Ther. Targets 21, 131\u2013143 (2017).","journal-title":"Expert Opin. Ther. Targets"},{"key":"400_CR13","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms4067","volume":"5","author":"L Lu","year":"2014","unstructured":"Lu, L. et al. Structure-based discovery of Middle East respiratory syndrome coronavirus fusion inhibitor. Nat. Commun. 5, 3067 (2014).","journal-title":"Nat. Commun."},{"key":"400_CR14","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms13473","volume":"7","author":"L Du","year":"2016","unstructured":"Du, L. et al. Introduction of neutralizing immunogenicity index to the rational design of MERS coronavirus subunit vaccines. Nat. Commun. 7, 13473 (2016).","journal-title":"Nat. Commun."},{"key":"400_CR15","doi-asserted-by":"publisher","first-page":"5757","DOI":"10.1128\/JVI.00083-06","volume":"80","author":"Y He","year":"2006","unstructured":"He, Y., Li, J., Heck, S., Lustigman, S. & Jiang, S. Antigenic and immunogenic characterization of recombinant baculovirus-expressed severe acute respiratory syndrome coronavirus spike protein: implication for vaccine design. J. Virol. 80, 5757\u20135767 (2006).","journal-title":"J. Virol."},{"key":"400_CR16","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1016\/S0140-6736(04)15788-7","volume":"363","author":"S Liu","year":"2004","unstructured":"Liu, S. et al. Interaction between heptad repeat 1 and 2 regions in spike protein of SARS-associated coronavirus: implications for virus fusogenic mechanism and identification of fusion inhibitors. Lancet 363, 938\u2013947 (2004).","journal-title":"Lancet"},{"key":"400_CR17","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.antiviral.2016.07.015","volume":"133","author":"Q Wang","year":"2016","unstructured":"Wang, Q., Wong, G., Lu, G., Yan, J. & Gao, G. F. MERS-CoV spike protein: targets for vaccines and therapeutics. Antivir. Res. 133, 165\u2013177 (2016).","journal-title":"Antivir. Res."},{"key":"400_CR18","doi-asserted-by":"publisher","first-page":"1864","DOI":"10.1126\/science.1116480","volume":"309","author":"F Li","year":"2005","unstructured":"Li, F., Li, W., Farzan, M. & Harrison, S. C. Structure of SARS coronavirus spike receptor-binding domain complexed with receptor. Science 309, 1864\u20131868 (2005).","journal-title":"Science"},{"key":"400_CR19","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1038\/nature12328","volume":"500","author":"G Lu","year":"2013","unstructured":"Lu, G. et al. Molecular basis of binding between novel human coronavirus MERS-CoV and its receptor CD26. Nature 500, 227\u2013231 (2013).","journal-title":"Nature"},{"key":"400_CR20","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1038\/nature02145","volume":"426","author":"W Li","year":"2003","unstructured":"Li, W. et al. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature 426, 450\u2013454 (2003).","journal-title":"Nature"},{"key":"400_CR21","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1038\/nature12005","volume":"495","author":"VS Raj","year":"2013","unstructured":"Raj, V. S. et al. Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC. Nature 495, 251\u2013254 (2013).","journal-title":"Nature"},{"key":"400_CR22","doi-asserted-by":"crossref","unstructured":"Zhou, P., et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 579, 270\u2013273\u00a0(2020).","DOI":"10.1038\/s41586-020-2012-7"},{"key":"400_CR23","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1126\/science.1118391","volume":"310","author":"W Li","year":"2005","unstructured":"Li, W. et al. Bats are natural reservoirs of SARS-like coronaviruses. Science 310, 676\u2013679 (2005).","journal-title":"Science"},{"key":"400_CR24","doi-asserted-by":"publisher","first-page":"12516","DOI":"10.1073\/pnas.1405889111","volume":"111","author":"Y Yang","year":"2014","unstructured":"Yang, Y. et al. Receptor usage and cell entry of bat coronavirus HKU4 provide insight into bat-to-human transmission of MERS coronavirus. Proc. Natl Acad. Sci. U. S. A. 111, 12516\u201312521 (2014).","journal-title":"Proc. Natl Acad. Sci. U. S. A."},{"key":"400_CR25","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1186\/1743-422X-10-266","volume":"10","author":"G Zhao","year":"2013","unstructured":"Zhao, G. et al. A safe and convenient pseudovirus-based inhibition assay to detect neutralizing antibodies and screen for viral entry inhibitors against the novel human coronavirus MERS-CoV. Virol. J. 10, 266 (2013).","journal-title":"Virol. J."},{"key":"400_CR26","doi-asserted-by":"publisher","first-page":"7045","DOI":"10.1128\/JVI.00433-14","volume":"88","author":"L Du","year":"2014","unstructured":"Du, L. et al. A conformation-dependent neutralizing monoclonal antibody specifically targeting receptor-binding domain in Middle East respiratory syndrome coronavirus spike protein. J. Virol. 88, 7045\u20137053 (2014).","journal-title":"J. Virol."},{"key":"400_CR27","doi-asserted-by":"publisher","first-page":"01651","DOI":"10.1128\/JVI.01651-16","volume":"91","author":"W Tai","year":"2017","unstructured":"Tai, W. et al. Recombinant receptor-binding domains of multiple Middle East respiratory syndrome coronaviruses (MERS-CoVs) induce cross-neutralizing antibodies against divergent human and camel MERS-CoVs and antibody escape mutants. J. Virol. 91, 01651\u201316 (2017).","journal-title":"J. Virol."},{"key":"400_CR28","doi-asserted-by":"publisher","first-page":"6170","DOI":"10.1016\/j.vaccine.2014.08.086","volume":"32","author":"C Ma","year":"2014","unstructured":"Ma, C. et al. Searching for an ideal vaccine candidate among different MERS coronavirus receptor-binding fragments-the importance of immunofocusing in subunit vaccine design. Vaccine 32, 6170\u20136176 (2014).","journal-title":"Vaccine"},{"key":"400_CR29","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.virol.2009.07.018","volume":"393","author":"L Du","year":"2009","unstructured":"Du, L. et al. Recombinant receptor-binding domain of SARS-CoV spike protein expressed in mammalian, insect and E. coli cells elicits potent neutralizing antibody and protective immunity. Virology 393, 144\u2013150 (2009).","journal-title":"Virology"},{"key":"400_CR30","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1089\/vim.2009.0090","volume":"23","author":"L Du","year":"2010","unstructured":"Du, L. et al. A 219-mer CHO-expressing receptor-binding domain of SARS-CoV S protein induces potent immune responses and protective immunity. Viral Immunol. 23, 211\u2013219 (2010).","journal-title":"Viral Immunol."},{"key":"400_CR31","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/j.virol.2016.10.005","volume":"499","author":"W Tai","year":"2016","unstructured":"Tai, W. et al. A recombinant receptor-binding domain of MERS-CoV in trimeric form protects human dipeptidyl peptidase 4 (hDPP4) transgenic mice from MERS-CoV infection. Virology 499, 375\u2013382 (2016).","journal-title":"Virology"},{"key":"400_CR32","doi-asserted-by":"publisher","first-page":"9939","DOI":"10.1128\/JVI.01048-13","volume":"87","author":"L Du","year":"2013","unstructured":"Du, L. et al. Identification of a receptor-binding domain in the S protein of the novel human coronavirus Middle East respiratory syndrome coronavirus as an essential target for vaccine development. J. Virol. 87, 9939\u20139942 (2013).","journal-title":"J. Virol."},{"key":"400_CR33","doi-asserted-by":"publisher","first-page":"29","DOI":"10.3389\/fmicb.2019.00029","volume":"10","author":"W Tai","year":"2019","unstructured":"Tai, W. et al. Transfusion-transmitted Zika virus infection in pregnant mice leads to broad tissue tropism with severe placental damage and fetal demise. Front. Microbiol. 10, 29 (2019).","journal-title":"Front. Microbiol."},{"key":"400_CR34","doi-asserted-by":"publisher","first-page":"648","DOI":"10.4161\/hv.27464","volume":"10","author":"WH Chen","year":"2014","unstructured":"Chen, W. H. et al. Yeast-expressed recombinant protein of the receptor-binding domain in SARS-CoV spike protein with deglycosylated forms as a SARS vaccine candidate. Hum. Vaccin. Immunother. 10, 648\u2013658 (2014).","journal-title":"Hum. Vaccin. Immunother."},{"key":"400_CR35","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1124\/pr.58.3.10","volume":"58","author":"TC Chou","year":"2006","unstructured":"Chou, T. C. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol. Rev. 58, 621\u2013681 (2006).","journal-title":"Pharmacol. Rev."}],"container-title":["Cellular &amp; Molecular Immunology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41423-020-0400-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41423-020-0400-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41423-020-0400-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T17:23:28Z","timestamp":1684603408000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41423-020-0400-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,19]]},"references-count":35,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,6]]}},"alternative-id":["400"],"URL":"https:\/\/doi.org\/10.1038\/s41423-020-0400-4","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.737584329.793572872","asserted-by":"object"}]},"ISSN":["1672-7681","2042-0226"],"issn-type":[{"value":"1672-7681","type":"print"},{"value":"2042-0226","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,19]]},"assertion":[{"value":"3 March 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 March 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 March 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}